DMAC - DiaMedica advances DM199 programs with $60M cash runway and expanded clinical trials
2025-08-13 11:37:01 ET
More on DiaMedica Therapeutics
- DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript
- DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer
- DiaMedica Therapeutics raises $30 million in private placement
- Seeking Alpha’s Quant Rating on DiaMedica Therapeutics
- Historical earnings data for DiaMedica Therapeutics